Pathways to Patient Access: The Strategic Role of Chargeable Expanded Access
Discover how global pricing pressure and staggered launches are reshaping patient access, and when chargeable expanded access may offer a sustainable pathway before launch or when commercialization is delayed.
Join us live on Thursday, November 19, 2026 at 5:00 pm CET / 11:00 am ET / 8:00 am PT.
Explore how pricing pressure and delayed or staggered launches are widening the gap between clinical development, approval and patient access.
Understand when chargeable expanded access may provide a sustainable pathway, including before launch or when commercialization is delayed or unfeasible.
Translate strategy into practice: recognize the regulatory, reimbursement and operational factors that determine whether chargeable expanded access is feasible in different markets.
Chief Business Officer (Expanded Access) at myTomorrows
PhD in Neurobiology, prior to joining myTomorrows, Karlijn obtained her PhD in neurodegenerative diseases; Karlijn oversees myTomorrows’ Expanded Access and Real-World Data business end to end, from partnership development through to program delivery and customer success. She brings more than a decade of experience in the Expanded Access space.
Mallory Fredericks
Director, Expanded Access Strategy & Customer Success at myTomorrows
Mallory brings 8+ years of experience in global managed access, spanning both strategic design and operational execution. She built and led the managed access function at SpringWorks Therapeutics (Merck KGaA) and played a key role in developing chargeable access frameworks and programs within market access.
